Renal Autologous Cell Therapy shows potential to preserve kidney function
Click Here to Manage Email Alerts
Key takeaways:
- Patients with diabetes and kidney disease had stabilized and preserved kidney function when using ProKidney’s Renal Autologous Cell Therapy.
- The study received FDA approval to begin a phase 3 study program.
AUSTIN, Texas — In this video, Kerry Cooper, MD, discusses the potential Renal Autologous Cell Therapy by ProKidney may have to preserve kidney function and slow the progression of kidney disease.
“The therapy involves obtaining tissue from the patient's own kidney via biopsy, expanding and enriching that population for cells that are thought to be involved in renal repair and regeneration,” Cooper, senior vice president of medical affairs at ProKidney, told Healio. “Then those cells are injected directly into the patient's own kidney sequentially, one and then the other, in our phase 3 studies.”
Following the early phase 2 clinical results in which Renal Autologous Cell Therapy (REACT) correlated with stabilized and improved kidney function among patients, the treatment has received FDA approval, European Medicines Agency approval and regenerative medicine advanced therapy designation to begin the phase 3 study program.
Collapse
Cooper K. et al. Poster 208. Presented at: National Kidney Foundation Spring Clinical Meetings; April 11-15, 2023; Austin, Texas.
Read more about
Click Here to Manage Email Alerts